H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $75 from $60 and keeps a Buy rating on the shares. The firm says Lifyorli and Korlym strength drove the company to increase its revenue guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler
- Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study
- Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth
- Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)
- Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M